Oct 19, 2019
Patients Rising Now is welcomes the opportunity to provide recommendations and comments about the pros and cons of ICER’s August 21st document outlining proposed changes to its Value Assessment Framework’s processes and methodology. As advocates for patients with...
Sep 13, 2016
Recently, the Institute for Clinical and Economic Review (ICER), released a scoping document outlining its intentions to evaluate the cost effectiveness of drugs used to treat the autoimmune disease Rheumatoid Arthritis (RA). ICER’s conclusions will be used by...
Sep 12, 2016
American Enterprise Institute presented a panel discussion around the costs of speciality drugs on September 12, 2016 in Washington D.C. Panelists included: Panelists: Gregg Alton, Gilead Peter B. Bach, Memorial Sloan Kettering Cancer Center Scott Gottlieb, AEI Joshua...
May 29, 2016
Here are the takeaways from the ICER meeting on” Treatment Options for Relapsed or Refractory Multiple Myeloma”. First, it is obvious that the Midwest Comparative Effectiveness Advisory Council is nothing but a cheap coat of paint used to poorly cover-up the fact...
May 26, 2016
Want to know what the future of health care could look like? You should pay attention to a little-known yet hugely important event taking place this Thursday. But don’t expect a rosy vision – what you’ll actually see is terrifying. The event in question is hosted by...
